Ana T. Nunes

Publications by Year

Research Areas

Ovarian cancer diagnosis and treatment, Immune cells in cancer, Cancer Immunotherapy and Biomarkers, Endometrial and Cervical Cancer Treatments, Reproductive System and Pregnancy

Most-Cited Works

• → Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial(2023)188 cited
• → Proteasome inhibitors: structure and function(2017)157 cited
• → BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).(2021)106 cited
• → CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study(2020)88 cited
• → Proportions and incidence of locally advanced cervical cancer: a global systematic literature review(2022)56 cited
• → 166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study(2022)43 cited
• → Monocyte and interferon based therapy for the treatment of ovarian cancer(2016)34 cited
• → A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer(2018)29 cited
• → Comparison of global treatment guidelines for locally advanced cervical cancer to optimize best care practices: A systematic and scoping review(2022)28 cited
• → 529MO Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer(2022)24 cited